A familiar consultation in a Moroccan law office begins with a surprisingly modest dispute. A patient arrives holding two pharmacy receipts. The same antihypertensive medicine cost him 15 dirhams more at his neighbourhood pharmacy than at an outlet in the city centre. He is angry, but also confused. Can pharmacies set their own prices? Is the amount printed on the medicine box binding? And is a difference of a few dirhams enough to justify a complaint?
The short answer is that most medicines marketed in Morocco are not ordinary consumer products whose retail prices fluctuate freely from one shop to another. A medicine authorised for sale is normally assigned a Prix public de vente, commonly described in practice as the Prix public maximum or PPM. The authorised price is determined through an administrative procedure and published or recorded by the health authorities. A pharmacy may not simply add a surcharge because the medicine is scarce, imported or requested outside normal opening hours.
The subject became particularly sensitive in 2024 after Moroccan economic media, including Medias24, reported the unexpected postponement of a planned price review. That episode exposed a deeper tension. Patients want affordable treatment. Manufacturers and importers face exchange-rate movements, higher raw-material costs and supply obligations. Pharmacists argue that declining margins threaten the viability of smaller outlets. The State, meanwhile, must finance the expansion of compulsory health insurance without encouraging shortages.
This article explains the regulation of medicine prices in Morocco, the role of marketing authorisation, the rules applicable to pharmacists and importers, CNSS reimbursement, and the remedies available when a patient is charged an unlawful price. It also corrects several persistent misconceptions, particularly regarding generic substitution, VAT and online medicine sales.
1. The legal foundations of medicine pricing in Morocco
1.1 Law No. 17-04: the backbone of pharmaceutical regulation
The central legislative text is Law No. 17-04 establishing the Code of Medicines and Pharmacy, promulgated by Dahir No. 1-06-151 of 22 November 2006 and published in Official Gazette No. 5480. It governs medicines, pharmaceutical establishments, manufacturing, importation, distribution and dispensing by pharmacies.
Law No. 17-04 must not, however, be presented as though Articles 62 to 68 constituted a self-contained retail pricing code. Those provisions form part of the broader regulation of pharmaceutical activity and professionals. The detailed price-setting methodology derives primarily from Decree No. 2-12-198 of 19 March 2013 on the pricing of medicines for human use and its implementing ministerial decisions.
The Code nevertheless establishes the essential legal sequence: a product must qualify as a medicine, obtain a valid Autorisation de mise sur le marché or AMM, be manufactured or imported through an authorised pharmaceutical establishment, and be dispensed through a lawful channel. Pricing approval does not cure the absence of an AMM, just as an AMM does not automatically authorise a company to charge any price it chooses.
Practical rule: marketing authorisation, price approval and lawful distribution are separate requirements. A business must satisfy all three before placing a medicine on the Moroccan retail market.
1.2 Decree No. 2-12-198 of 19 March 2013
Decree No. 2-12-198, published in Official Gazette No. 6142 of 4 April 2013, reorganised the Moroccan pricing system. Its opening provisions establish a regulated public selling price for medicines for human use, while the following provisions distinguish between locally manufactured products, imported medicines, originator products and generics.
For an originator medicine, the administration examines the manufacturer price and international comparators identified by the regulatory methodology. For an imported product, the declared import value, the price in the country of origin or export, exchange-rate information and other supporting evidence may be reviewed. Generic medicines are priced by reference to the corresponding originator and the applicable reduction mechanism.
The decree must be read together with its implementing orders and later price decisions. This matters because a ministerial decision may reduce the price of a particular presentation without amending the decree itself. The legally relevant product is not merely the brand name: dosage, pharmaceutical form, pack size and presentation must also match.
1.3 Ministerial price decisions and the Official Gazette
The Ministry of Health approves and revises medicine prices through regulatory and individual administrative instruments. Historically, the technical work was carried out by the Direction du médicament et de la pharmacie, later referred to within the Ministry's reorganised structure alongside medical logistics functions. Morocco has since pursued an institutional transition toward the Moroccan Agency for Medicines and Health Products under Law No. 10-22. For a file initiated in 2024, however, the competent authority and procedural address must be checked against the administrative organisation then in force.
The General Secretariat of the Government and the Official Gazette remain the safest sources for legislative and regulatory texts. Ministry price databases are useful operational tools, but a screenshot from a commercial website does not have the same evidentiary value as an official decision or authenticated administrative record.
1.4 Competition law still applies to the pharmaceutical sector
Law No. 104-12 on freedom of prices and competition, promulgated by Dahir No. 1-14-116 of 30 June 2014, starts from the principle in Article 2 that prices of goods and services are freely determined through competition, subject to the statutory exceptions. Medicines fall within a special regulated regime because public health, supply constraints and market characteristics justify administrative intervention.
This exception does not place pharmaceutical operators outside competition law. Article 6 of Law No. 104-12 prohibits concerted actions, agreements and arrangements whose object or effect is to prevent, restrict or distort competition. Article 7 addresses abuse of a dominant position and abuse of economic dependence. Consequently, wholesalers cannot lawfully allocate territories or coordinate discounts, and a dominant laboratory cannot use its market power in a manner prohibited by law.
The Competition Council, governed institutionally by Law No. 20-13, examines market behaviour. It does not replace the Ministry of Health in approving the PPM. In clear terms, the Ministry regulates the authorised price; the Council investigates anticompetitive conduct. Businesses facing exclusionary practices should consult a Moroccan competition lawyer before filing a technically complex referral.
2. How is the retail price of a medicine calculated?
2.1 From the manufacturer to the patient
The price paid at the pharmacy results from several regulated components. These ordinarily include the manufacturer price excluding tax for a locally produced medicine, or an approved import-related basis for an imported product, followed by the authorised wholesale and pharmacy remuneration. The applicable tax treatment must then be considered.
Older explanations of Moroccan medicine pricing often add VAT at 7%. That was historically relevant to many pharmaceutical products, but it is incomplete for 2024. The VAT reform introduced by Finance Law No. 55-23 for the 2024 financial year changed the treatment of medicines and pharmaceutical inputs from 1 January 2024. Therefore, a calculation for a 2024 transaction should not mechanically add 7% using an outdated model. The precise customs and VAT position must be verified under the General Tax Code and the transition rules applicable to the product and transaction date.
A simplified illustration helps. Suppose the approved economic chain begins with a manufacturer basis of 70 dirhams. Regulated remuneration may bring the wholesale transfer price and pharmacy price to 100 dirhams. The patient owes the officially approved retail amount shown for that exact presentation, not 100 dirhams plus an informal scarcity premium. This example is explanatory only: it is not a substitute for the official price decision, and margins cannot reliably be reconstructed by applying one percentage to every medicine.
2.2 The legal pharmacy margin in Morocco
The expression marge bénéficiaire pharmacien Maroc is frequently misunderstood. Turnover margin is not net profit. From the pharmacy's regulated remuneration must come rent, wages, social contributions, inventory financing, expired stock, electricity, professional insurance and on-call obligations.
The distribution system is broadly degressive: the remuneration structure becomes proportionally lower as the medicine's price rises, with specific bands or fixed amounts applicable to expensive products. Public discussions often cite a rate around 30% for lower-priced products and a much lower rate for costly medicines. Those figures should not be applied in isolation, because the legal basis, price band, generic status and calculation base all matter. The relevant ministerial schedule in force on the sale date must be consulted.
Nor should a patient assume that the difference between the manufacturer price and retail price belongs entirely to the pharmacist. Part remunerates the wholesale distributor; tax and regulatory elements may also intervene. A pharmaceutical operator auditing its margins should obtain the applicable orders and seek advice from a pharmaceutical business lawyer in Morocco.
2.3 Generic medicines: lower prices, but no blanket substitution right
A generic medicine contains the same active substance and must satisfy the applicable standards of pharmaceutical equivalence and, where required, bioequivalence. Its approved price is normally lower than that of the originator because the regulatory methodology applies a reference reduction.
One recurring claim deserves correction: Moroccan law has not historically granted pharmacists an unrestricted, general right to replace every prescribed branded medicine with a generic of their own choosing. Generic substitution has been repeatedly debated as a health-policy reform, but a policy objective is not the same thing as an enacted and operational substitution rule. Pharmacists must respect prescription rules, professional duties and the exact legislation in force. Patients should therefore ask the prescriber or pharmacist about an available generic rather than assume that substitution is automatic.
Similarly, there is no single instrument accurately described as the “Moroccan generic medicines decree” that settles every issue of pricing, prescribing, substitution and reimbursement. These matters arise from Law No. 17-04, Decree No. 2-12-198, AMM rules, price decisions, reimbursement instruments and professional regulation.
2.4 Imported medicines
Imported medicines remain subject to Moroccan AMM and price approval requirements. An authorisation issued in France, Spain or another reference market does not permit automatic sale in Morocco. The importing entity must hold the required pharmaceutical establishment authorisation, comply with quality and traceability obligations, clear customs and sanitary controls, and submit reliable pricing documentation.
The administration may examine the foreign ex-factory price, export price, import value and official exchange data. But it is misleading to say that an importer may simply convert a European pharmacy price into dirhams. Retail prices abroad contain taxes and distribution margins that may not be comparable with the Moroccan calculation.
Disputes can concern customs classification, cold-chain compliance, batch release, documentary discrepancies or a refusal to approve the requested price. These cases often require coordinated advice from regulatory counsel and an import-export lawyer in Morocco.
3. Marketing authorisation: the gateway to pricing and lawful sale
3.1 The Moroccan AMM procedure
The AMM médicament Maroc procédure begins with a dossier identifying the applicant and manufacturer and documenting pharmaceutical quality, safety and efficacy. Depending on the product, the authority may require manufacturing information, stability studies, analytical methods, preclinical and clinical data, bioequivalence evidence, proposed labelling, pharmacovigilance arrangements and certificates concerning the manufacturing site.
The often-quoted review period is 210 days. It should not be mistaken for a guaranteed calendar deadline. Requests for additional documents can stop or disrupt the review timetable, and sector professionals have reported total processing periods of 18 to 24 months for some files. Product complexity, foreign-site documentation and exchanges over the proposed price can lengthen the process.
Official filing and expert-assessment charges depend on the category of application and the fee schedule in force. It would be unsafe to publish one universal amount: a generic application, a new active substance, a variation and a renewal do not necessarily generate the same fees. Before filing, the applicant should obtain the current schedule directly from the competent authority and budget separately for legalisation, translation, laboratory analysis and local regulatory representation.
3.2 AMM and price approval are distinct
An applicant may satisfy the scientific requirements for an AMM while disagreeing with the administration over the proposed retail price. Conversely, a favourable discussion about price does not authorise sale before the AMM and the necessary administrative acts are issued.
Marketing without a valid AMM exposes the operator to the offences and enforcement measures contained in Law No. 17-04, including its criminal provisions beginning at Article 133. Depending on the conduct, consequences may include seizure, closure measures, fines and imprisonment. References sometimes made to “Articles 83 and following” as the general criminal basis are inaccurate: the Code's numbering and subject matter must be checked in the official consolidated text.
A refusal, withdrawal or prolonged administrative silence may justify a gracious appeal, a hierarchical approach or, where the legal conditions are met, proceedings before the administrative courts. Since the central authority is based in Rabat, many regulatory disputes require assistance from a health-law lawyer in Rabat. Urgent suspension proceedings are possible in Moroccan administrative litigation, but urgency and serious doubt as to legality must be demonstrated; they are not automatic.
3.3 Renewal and variations
An AMM is not a licence to freeze the product forever. Changes to the manufacturer, production site, composition, packaging, indications or pharmacovigilance information may require a prior variation. Renewal requirements must also be monitored under the Code and implementing rules.
A variation does not automatically entitle the holder to a higher PPM. If the company seeks a price revision because of exchange rates, input costs or a new presentation, it must use the relevant price-review procedure and provide evidence. Selling at the requested price before approval creates obvious enforcement risk.
4. Who controls medicine prices in Moroccan pharmacies?
4.1 The Ministry of Health and pharmaceutical inspectors
The Ministry is the central pricing and pharmaceutical-control authority. Pharmaceutical inspectors may verify authorisations, invoices, storage conditions, registers, traceability, labelling and retail practices within the powers granted by Law No. 17-04. Properly established reports can be transmitted to the competent administrative authority or public prosecutor.
On paper, the control chain is substantial. On the ground, staffing and geographical coverage remain real constraints. Morocco has thousands of pharmacies, distributors, clinics and pharmaceutical operators. Inspections cannot be continuous, which is why receipts, batch details, photographs and precise consumer reports matter.
4.2 Price information and consumer law
Article 3 of Law No. 31-08 establishing consumer-protection measures requires suppliers to provide consumers with information enabling an informed choice, including essential characteristics and price. Implementing price-display rules supplement that obligation. In a pharmacy, the approved price printed on the box and the official database are particularly important evidence.
Nevertheless, not every apparent discrepancy proves fraud. A patient may be comparing different dosages, pack sizes, manufacturers or presentations. A delivery charge for a separate service may also be confused with the medicine price. Before accusing the pharmacist, compare the barcode, dosage, number of units and approved PPM.
4.3 The Competition Council's complementary role
The Competition Council may investigate agreements between laboratories or wholesalers, exclusionary practices, discriminatory access to supply or abuse by a dominant operator. It has also used sector studies and opinions to examine competitive conditions in regulated markets. Such analysis can influence reform, but it does not itself rewrite the retail price printed for a medicine.
A complaint to the Council should identify the market, parties, conduct, duration and anticompetitive effect. A dispute involving only one incorrect pharmacy receipt is normally better directed to health inspectors or consumer-protection authorities.
4.4 The postponed 2024 price review
The reported postponement of the 2024 revision generated uncertainty for patients and industry. The publicly discussed explanations included inflation, the dirham's movement against import currencies, pressure from manufacturers, purchasing-power concerns and technical disagreements over the methodology. Unless supported by an official decision or statement, however, those explanations should be treated as analysis rather than established legal fact.
A postponed general reform does not suspend existing PPMs. Until a new price is lawfully approved, the price already in force continues to bind the operator. A press report announcing a possible increase is not a legal authorisation to charge it.
5. CNSS and AMO reimbursement of medicines
5.1 The governing framework
Law No. 65-00 establishing the Code of Basic Medical Coverage provides the legislative basis for compulsory health insurance. Medicines form part of the benefits that may be covered subject to the reimbursement rules, medical necessity, prescription requirements and the applicable reimbursable list.
For a CNSS-insured patient, the decisive questions are whether the medicine is included in the reimbursable nomenclature, whether the prescription complies with the rules, and what reference tariff applies. Reimbursement should not be described automatically as 70% of the amount actually paid or 70% of the PPM. In ordinary outpatient care, a 70% coverage rate is commonly used, but it is applied under AMO rules to the relevant national reference tariff and subject to exclusions and formalities.
Long-term or costly conditions may benefit from exemption from the co-payment or enhanced coverage, subject to prior recognition and medical-control procedures. “ALD” status does not mean that every medicine purchased by the patient is automatically reimbursed at 100%; the treatment must be related to the recognised condition and satisfy the applicable rules.
5.2 Documents and practical processing
A reimbursement file generally includes the appropriate treatment form, the original prescription, proof of purchase or pharmacy documents, patient and insured-person identification, and any supporting medical evidence requested for the treatment. Patients should retain copies before submitting originals.
Incomplete files are a common cause of delay. So are discrepancies between the prescribed product and the product dispensed. Processing time varies with the file, agency workload and whether medical control is required. Rather than relying on an assumed statutory 60-day appeal period, read the refusal notice carefully: it should identify the reason, competent review body and deadline. Different disputes may follow different procedures.
5.3 Challenging a refusal
Begin with a written request for reasons and an internal or amicable review. Attach the prescription, receipt, medical report, reimbursable-list reference and proof of insurance rights. Obtain a stamped receipt or send the claim by a method proving delivery.
If the medicine is not on the reimbursable list, the fact that a doctor prescribed it does not by itself compel CNSS reimbursement. The patient may nevertheless challenge a classification error, unequal application of the rules or failure to consider an approved exception. Depending on the legal nature of the decision and the claim sought, jurisdiction can raise technical questions between social-security litigation and administrative litigation. It is therefore unsafe to state that every CNSS reimbursement case belongs automatically before the administrative court.
For a modest sum, paying a lawyer to litigate may cost more than the disputed reimbursement. An initial written claim is usually proportionate. Repeated refusals involving expensive chronic treatment justify advice from a Moroccan administrative-law lawyer or counsel experienced in social-security disputes.
6. What can a patient do if a pharmacy charges too much?
6.1 Build the evidence first
A credible recours juridique prix abusif médicament Maroc begins with evidence, not anger. Keep the medicine box, receipt, prescription and payment record. Photograph the price printed on the box without damaging the batch number. Record the pharmacy's name, address, date and time, and compare the exact presentation with the official price source.
Ask the pharmacist for an itemised receipt and a calm explanation. A data-entry error may be corrected immediately.
If the difference remains unexplained, submit a written report to the competent Ministry of Health service or pharmaceutical inspectorate.
Send a consumer complaint through the Ministry of Industry and Trade's consumer-protection portal or contact a recognised consumer association.
Where there is deliberate fraud, repeated conduct or significant harm, file a complaint with the territorially competent Procureur du Roi at the Court of First Instance, or report the facts to the competent administrative authority.
The complaint should state facts, not legal conclusions alone. “The pharmacy is dishonest” is weak. “On 12 June, presentation X, 10 mg, 30 tablets, bearing an approved price of 84.50 MAD, was invoiced at 99.50 MAD; receipt and box attached” is useful.
6.2 Is sale above the PPM a criminal offence?
Charging above a binding regulated price can trigger administrative and criminal consequences under the pharmaceutical and price-control framework. However, frequently circulated references to Article 57 of Law No. 104-12 as though it directly and exclusively created the offence of overcharging for medicines are unreliable. The applicable prosecution provision depends on the conduct, the regulatory price decision and the enforcement route.
Possible consequences include a formal report, prosecution, fine, seizure-related measures and professional or establishment sanctions where the legal conditions are satisfied. Closure is not automatic; it requires a statutory basis and compliance with procedure. The pharmacist retains rights of defence before the competent authority and courts.
A patient who suffered provable loss may seek compensation under the ordinary rules of civil liability, including Articles 77 and 78 of the Dahir forming the Code of Obligations and Contracts. For an overcharge of 15 dirhams, though, individual litigation is rarely economical. A collective pattern affecting many consumers is different and may justify coordinated action through a consumer association.
A lawyer's practical advice: before starting court proceedings over a few dirhams, assess the cost-benefit ratio. A documented administrative complaint to the health authority or consumer-protection service is usually faster and less expensive for an individual patient.
6.3 Consumer associations and legal assistance
Recognised consumer associations can help document repeated practices, communicate with authorities and, within the conditions of Law No. 31-08, defend collective consumer interests. Patients may also consult a consumer-law lawyer in Morocco. Where forged invoices, counterfeit medicines or organised deception are suspected, criminal-law advice may be needed, particularly from an criminal lawyer in Casablanca if the facts occurred there.
One should be cautious with dramatic stories circulated on social media. Without a receipt, exact product reference and official price comparison, it is impossible to verify claims of a 40% surcharge. A serious legal article should not invent a Casablanca judgment or attribute an outcome to an unpublished case.
7. Reform, industrial pressure and medicine affordability
7.1 Why price revision is politically difficult
A lower medicine price benefits patients and AMO finances in the short term. But a price below sustainable supply cost can encourage withdrawal of low-volume products, delay launches or weaken local production. Conversely, generous prices increase household expenditure and compulsory-insurance costs. The regulator is constantly balancing access, supply security and industrial viability.
Manufacturers seek recognition of inflation, energy costs, imported active ingredients and exchange-rate risk. Wholesalers stress the cost of nationwide distribution, including remote areas and cold-chain products. Pharmacists point to fixed operating costs. Patients, quite reasonably, ask why Moroccan prices for some brands remain high compared with household income.
7.2 Local manufacturing and health sovereignty
Morocco has a significant domestic pharmaceutical manufacturing base, often credited with covering a substantial share of national demand by volume. Exact percentages vary by year and methodology, so claims such as “60% of the market” should always identify whether they refer to units, value or national consumption.
Local production reduces some import risks but does not eliminate dependence. Active pharmaceutical ingredients, excipients, packaging equipment and specialised technology may still be imported. A sovereign-health policy therefore requires more than price increases: it needs predictable procurement, quality investment, transparent AMM timelines and incentives targeted at genuinely strategic products.
7.3 Toward a more transparent system
A credible reform could combine regular international benchmarking with cost and supply evidence, publish clearer reasons for price decisions, accelerate generic and biosimilar assessment, and create an accessible official database showing current and historical prices. Procedural deadlines should distinguish between active review time and periods awaiting applicant responses.
Reimbursement policy should also be coordinated with pricing. Reducing the PPM does not fully help a patient if the medicine remains outside the reimbursable list. Likewise, adding a product to reimbursement without ensuring adequate supply may create a paper entitlement but no practical access.
The 2024 postponement was therefore more than an administrative delay. It revealed weaknesses in transparency and stakeholder confidence. Any future reform should involve patients, pharmacists, wholesalers, manufacturers, CNSS, health economists and the Competition Council, while keeping the final decision anchored in public health rather than lobbying power.
Conclusion: a regulated price is a legal protection, not merely a label
Morocco possesses a substantial legal framework for medicine pricing. Law No. 17-04 controls pharmaceutical products and operators; Decree No. 2-12-198 establishes the pricing methodology; Law No. 104-12 addresses competition; Law No. 31-08 protects consumer information; and Law No. 65-00 structures AMO coverage.
The weakness lies less in the absence of texts than in fragmented information, lengthy authorisation procedures, limited inspection resources and sometimes opaque reform timetables. Patients should keep receipts and compare exact presentations. Professionals should never treat a requested price as an approved price. Importers and manufacturers must separate AMM, pricing, customs and reimbursement workstreams.
For a simple overcharge, a written administrative complaint is usually the sensible first step. For repeated overpricing, an AMM refusal, a major CNSS reimbursement dispute or an anticompetitive practice, specialised legal advice may be justified. A health-law lawyer in Casablanca or another competent Moroccan practitioner can assess the evidence, jurisdiction, deadlines and realistic cost before proceedings begin.
